JANX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
9.3M
-9.5%
10.3M
+175.0%
3.7M
0
-100.0%
10.0M
Cost of Revenue
0
0
0
0
0
Gross Profit
9.3M
-9.5%
10.3M
+175.0%
3.7M
0
-100.0%
10.0M
Operating Expenses
40.5M
-3.4%
42.0M
+10.6%
37.9M
-10.5%
42.4M
-6.3%
45.3M
R&D
30.6M
-1.4%
31.0M
+15.6%
26.8M
-15.0%
31.5M
-8.9%
34.6M
SG&A
10.0M
-8.9%
11.0M
-1.5%
11.1M
+2.6%
10.9M
+2.2%
10.6M
Operating Income
-31258000
+1.4%
-31690000
+7.4%
-34213000
+19.3%
-42401000
-20.3%
-35251000
EBITDA
-30800000
+1.4%
-31227000
+7.5%
-33744000
+19.5%
-41933000
-20.7%
-34750000
Net Income
-21570000
+1.8%
-21972000
+9.8%
-24361000
+23.7%
-31946000
-31.4%
-24313000
EPS (Basic)
$-0.34
+2.9%
$-0.35
+10.3%
$-0.39
+23.5%
$-0.51
-30.8%
$-0.39
EPS (Diluted)
$-0.34
+2.9%
$-0.35
+10.3%
$-0.39
+23.5%
$-0.51
-30.8%
$-0.39
Shares (Diluted)
63.1M
+0.2%
62.9M
+0.4%
62.7M
+0.8%
62.2M
+0.2%
62.0M
Janux Therapeutics (JANX) — Financials